Two deals totalling $560 million. Both are closing within months. Both are targeting the same sector cluster. Infosys announced the acquisitions of healthcare technology firms late Wednesday, boosting its fiscal-year M&A spend to an all-time high.
The timing raises governance questions that boards should examine closely. Record-high acquisition spending in a single fiscal year, concentrated in adjacent sectors, with accelerated closure timelines, suggests strategic urgency that may not align with typical board oversight cycles.
Infosys expects the acquisitions to generate $319 million in incremental revenue, implying a revenue multiple of approximately 1.8x. Healthcare and insurance technology firms typically trade at higher multiples, particularly in the current market. The pricing appears aggressive for assets that will require integration across geographies and business models.
The all-cash structure eliminates dilution concerns but raises questions about capital allocation. For a company sitting on substantial cash reserves, the deployment of $560 million in a concentrated timeframe suggests either exceptional deal availability or pressure to deploy capital quickly. Neither scenario is inherently problematic, but both require board-level strategic review.
The announcement does not address the due diligence timeline. Two major acquisitions announced simultaneously, both expected to close by June, imply parallel processing of complex transactions. The board’s role in approving concurrent due diligence processes becomes critical when deal sizes reach this magnitude.
The healthcare and insurance technology focus aligns with Infosys’ stated digital transformation strategy. However, sector concentration in M&A carries execution risks that boards must evaluate. Integration challenges multiply when acquired firms operate in similar markets but may compete in service lines.
My Boardroom Takeaway:
Independent directors should scrutinize the board’s role in approving this acquisition timeline. When M&A spending reaches record levels in a single fiscal year, the board may wish to consider whether approval processes adequately evaluated strategic alternatives to concentrated sector betting. The real governance question is not whether these deals create value, but whether the board had sufficient time and information to evaluate that concentration risk against alternative deployment strategies.